[Federal Register Volume 63, Number 246 (Wednesday, December 23, 1998)]
[Notices]
[Page 71145]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-33916]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Peripheral and Central Nervous System Drugs Advisory Committee; 
Notice of Meeting

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

     This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committee: Peripheral and Central Nervous System Drugs 
Advisory Committee.
    General Function of the Committee: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on January 29, 1999, 8:30 
a.m. to 5 p.m.
    Location: Holiday Inn, Kennedy Grand Ballroom, 8777 Georgia Ave., 
Silver Spring, MD.
    Contact Person: Ermona B. McGoodwin or Mae Brooks, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory 
Committee Information Line, 1-800-741-8138 (301-443-0572 in the 
Washington, DC area), code 12543. Please call the Information Line for 
up-to-date information on this meeting.
    Agenda: The committee will discuss new drug application (NDA) 21-
000, cladribine (MylinaxTM, R. W. Johnson Pharmaceutical 
Research Institute) for the treatment of relapsing-remitting and 
secondary progressive multiple sclerosis.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by January 22, 
1999. Oral presentations from the public will be scheduled between 
approximately 1 p.m. and 2 p.m. Time allotted for each presentation may 
be limited. Those desiring to make formal oral presentations should 
notify the contact person before January 22, 1999, and submit a brief 
statement of the general nature of the evidence or arguments they wish 
to present, the names and addresses of proposed participants, and an 
indication of the approximate time requested to make their 
presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: December 16, 1998.
Michael A. Friedman,
Deputy Commissioner for Operations.
[FR Doc. 98-33916 Filed 121-22-98; 8:45 am]
BILLING CODE 4160-01-F